{
    "nctId": "NCT00477919",
    "briefTitle": "E-MOSAIC Electronic Tool to Monitor Symptoms",
    "officialTitle": "E-MOSAIC: A Multicenter Randomized Controlled Phase III Study of Longitudinal Electronic Monitoring of Symptoms and Syndromes Associated With Advanced Cancer in Patients Receiving Anticancer Treatment in Palliative Intention",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 264,
    "primaryOutcomeMeasure": "Determine the effect of an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC) and a Longitudinal Monitoring Sheet (LoMoS) on global quality of life (G-QOL)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of advanced incurable cancer\n* Symptomatic disease, defined as meeting \u2265 1 of the following criteria:\n\n  * Pain Visual Analogue Scale (VAS) \u2265 3/10 and/or morphine equivalent daily dose of \u2265 10 mg for \u2265 3 days\n  * Anorexia VAS \u2265 3/10 and/or weight loss of \u2265 2% in 2 months or \u2265 5% in 6 months\n  * Fatigue VAS \u2265 3/10 and/or Karnofsky performance status \\< 70%\n  * Depression or anxiety VAS \u2265 3/10 and/or treatment with antidepressants for \u2265 5 days and planned for \u2265 1 month\n* Receiving continuously, weekly, or biweekly palliative anticancer treatment meeting 1 of the following criteria:\n\n  * At least 1 first-line treatment for any of the following:\n\n    * Metastatic melanoma\n    * Renal cell cancer\n    * Pancreatic cancer\n    * Biliary tract cancer\n    * Mesothelioma\n    * Prostate cancer (chemotherapy)\n    * Advanced glioblastoma\n  * At least 1 second-line treatment for any of the following:\n\n    * Extensive stage small cell lung cancer\n    * Stage IV non-small cell lung cancer\n    * Colorectal cancer\n    * Gastric cancer\n    * Esophageal cancer\n    * Bladder cancer\n    * Sarcoma\n    * Carcinoma of unknown primary\n  * At least 1 third-line chemotherapy regimen for any of the following:\n\n    * Metastatic breast cancer\n    * Ovarian cancer\n* Anticancer treatment must be given in an outpatient setting, not within a clinical trial, with weekly monitoring, and expected tumor response rate \u2264 20% according to the literature\n* No testicular cancer\n* No hematological malignancies\n* No primary brain tumors other than glioblastoma\n* Physician characteristics:\n\n  * No change to standard of care for symptom assessment or to major communication skills strategies within the past 3 months\n  * Experienced in medical oncology (i.e., worked \u2265 50% in clinical oncology within the past 24 months)\n  * Likely to stay in the participating institution for the time required to treat \u2265 5 study patients\n  * Able to independently communicate with the patient about all aspects of cancer care\n  * Able to independently perform immediate changes of interventions in patient care without the institutional requirement to counsel another colleague before prescribing (i.e., for symptom control)\n  * Completed a basic communication skills course or equivalent training (i.e., familiar with communication skills)\n\nPATIENT CHARACTERISTICS:\n\n* Able to understand assessment instrument language\n* Able to understand physician communication without difficulty (i.e., due to culture, language, speech)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No concurrent participation in another clinical trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}